Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05590585 · ClinicalTrials.gov registry record · Phase 4
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
A Phase 4 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 124
- Enrollment target
NCT05590585 is a Phase 4 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 124 participants.
The verdict
NCT05590585, a Phase 4 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 124 participants
- Enrollment target
Study Summary
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in your blood at different times * How much the study drug improves quality of life and mental health
Interventions
- DRUG dupilumab
- OTHER Topical emollient (moisturizer)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05590585
The ClinicalTrials.gov registry entry for NCT05590585 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dupilumab is the first listed.
NCT05590585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05590585 about?
NCT05590585 is a clinical study titled "Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial". The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an ...
What is the current status of trial NCT05590585?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 124 participants. The study started on 2023-01-11. Estimated completion is 2024-11-14.
What interventions are being tested in trial NCT05590585?
The interventions under investigation include: dupilumab (DRUG), Topical emollient (moisturizer) (OTHER).
Who is sponsoring clinical trial NCT05590585?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.